Jump to navigation

Home

N4 Pharma

  • Home
  • About
    • Experienced Board
      • Nigel Theobald
      • Paul Titley
      • Dr David Templeton
      • Luke Cairns
    • Our business
    • Our history
    • Our model
  • Generics
  • Vaccines
  • Patents
  • Pipeline
    • Sildenafil
    • Nuvec
    • Aprepitant
    • Sartans
    • Single dose Hep B
    • Duoloxetine
  • Investors
    • AIM Rule 26
      • AIM Securities Information
      • Advisers
      • Corporate Governance and Director Responsibilities
    • Investor Information
      • Company Reports
      • N4 Pharma Investor Presentations
    • Regulatory News
    • Other News
  • Contact Us
Back to top

  • Generics reformulation

    Reformulating existing drugs to improve their performance

    Read more

  • Vaccines and Therapeutics

    Silica nanoparticles to improve the delivery of vaccines and therapeutics

    Read more

  • History

    Established in 2014 and listed on the AIM market of the London Stock Exchange in May 2017

    Read more

  • Current Pipeline

    The Company is engaged in a range of opportunities across two divisions

    Read more

Pipeline

N4 Pharma has a wide range of products backed by patent applications. Near term focus of the Company is on the following products/opportunities.

Sildenafil

Erectile Dysfunction
Nuvec

Nuvec

Aprepitant

Oncology and pain relief

Read more about our full Pipeline

Contact us for further information

Contact us

Copyright © 2017 N4 Pharma. All rights reserved.

Address: Weston house, Bradgate Park View, Chellaston, Derbyshire, DE73 5UJ
Email address: info@n4pharma.com

Privacy Policy | Terms and Conditions